+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of ruxolitinib cream in children aged 6 to under 12 years old who have nonsegmental vitiligo. This phase 3 study aims to understand how well ruxolitinib cream works to improve skin depigmentation in this young population. The study compares two strengths of ruxolitinib cream against a placebo cream, with participants randomly assigned to one of the groups. Participants apply either 0.75% or 1.5% ruxolitinib cream, or a matching placebo cream, as a thin layer on the affected skin areas twice daily. The treatment lasts for 24 weeks, with the primary goal of measuring improvement in facial vitiligo area. The study also monitors other outcomes such as body vitiligo improvement, patient satisfaction, and possible side effects for up to 52 weeks. During the study, participants will be regularly assessed for changes in their vitiligo using standardized scoring indexes and questionnaires that measure the impact on quality of life. Blood samples will be taken at several points to study the drugs levels in the body. Safety is closely monitored, and participants are followed through a final safety visit. Overall participation can last up to around one year, including treatment and follow-up periods.

Age: 6Years - 11YearsAll GendersPhase 3
78 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Researchers are evaluating how well ACT-777991 works, its safety, and how well it is tolerated by adults with non-segmental vitiligo. The main goal is to find out if ACT-777991 can help restore skin color on the face compared to a placebo, which is an inactive treatment. This phase 2a clinical trial is randomized, double-blind, and placebo-controlled, aiming to assess the treatments effects in adults aged 18 to 65 with this condition. Participants will be randomly assigned in a 21 ratio to receive either ACT-777991 tablets or placebo tablets taken orally every day for 24 weeks. The trial includes three periods screening to confirm eligibility, a 24-week treatment period, and a follow-up period lasting up to 37 days after treatment ends. During treatment, participants will take the assigned tablets daily and attend scheduled clinic visits. Throughout the study, participants will visit the clinic seven times for check-ups and tests. Researchers will monitor changes in the facial Vitiligo Area Scoring Index F-VASI at multiple points, including weeks 4, 8, 16, and 24, using both independent blinded readings and investigator assessments. Other assessments include total body vitiligo area, safety labs, vital signs, and heart monitoring. After treatment, participants will have a follow-up visit to assess any ongoing effects, with the entire trial lasting about 33 weeks per participant.

Age: 18Years - 65YearsAll GendersPhase 2
5 locations
P

Actively Recruiting

This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.

Age: 18Years +All GendersPhase 3
306 locations